ProjectKOMET Studie
Basic data
Title:
KOMET Studie
Duration:
12/10/2021 to 31/10/2024
Abstract / short description:
Klinische Prüfung - KOMET Studie
A Phase III. Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NFI who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET).
A Phase III. Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NFI who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET).
Involved staff
Managers
Department of Neurosurgery
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine
Other staff
Department of Neurosurgery
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine
Department of Neurosurgery and Neurotechnology, Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Department of Neurosurgery and Neurotechnology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Hamburg, Germany